Vident Investment Advisory LLC Acquires 60,608 Shares of Five Prime Therapeutics Inc (FPRX)

Vident Investment Advisory LLC raised its holdings in Five Prime Therapeutics Inc (NASDAQ:FPRX) by 74.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 142,154 shares of the biotechnology company’s stock after purchasing an additional 60,608 shares during the period. Vident Investment Advisory LLC’s holdings in Five Prime Therapeutics were worth $2,247,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Rockefeller Capital Management L.P. purchased a new position in shares of Five Prime Therapeutics in the first quarter worth about $111,000. Quantbot Technologies LP increased its stake in shares of Five Prime Therapeutics by 361.5% in the first quarter. Quantbot Technologies LP now owns 7,347 shares of the biotechnology company’s stock worth $126,000 after purchasing an additional 5,755 shares in the last quarter. Mackay Shields LLC purchased a new position in shares of Five Prime Therapeutics in the first quarter worth about $317,000. Alambic Investment Management L.P. purchased a new position in shares of Five Prime Therapeutics in the second quarter worth about $351,000. Finally, Fox Run Management L.L.C. purchased a new position in shares of Five Prime Therapeutics in the second quarter worth about $379,000. Hedge funds and other institutional investors own 86.31% of the company’s stock.

FPRX stock opened at $13.53 on Friday. Five Prime Therapeutics Inc has a 12 month low of $12.52 and a 12 month high of $48.87. The company has a market capitalization of $511.63 million, a PE ratio of -2.51 and a beta of 3.24.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.99) EPS for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.30. Five Prime Therapeutics had a negative net margin of 206.02% and a negative return on equity of 40.61%. The company had revenue of $7.58 million during the quarter, compared to analyst estimates of $5.87 million. analysts predict that Five Prime Therapeutics Inc will post -4.02 EPS for the current fiscal year.

Several equities analysts have recently weighed in on the stock. BidaskClub upgraded shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, June 27th. JPMorgan Chase & Co. assumed coverage on shares of Five Prime Therapeutics in a research note on Friday, June 15th. They issued a “neutral” rating and a $19.00 target price for the company. Raymond James assumed coverage on shares of Five Prime Therapeutics in a research report on Thursday, June 28th. They issued a “market perform” rating for the company. Zacks Investment Research lowered shares of Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, June 27th. Finally, ValuEngine upgraded shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 2nd. Two analysts have rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $31.70.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Featured Article: What is a Stop Order?

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics Inc (NASDAQ:FPRX).

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply